AC Immune SA Files 6-K for Shareholder Meetings

Ticker: ACIU · Form: 6-K · Filed: May 21, 2024 · CIK: 1651625

Ac Immune SA 6-K Filing Summary
FieldDetail
CompanyAc Immune SA (ACIU)
Form Type6-K
Filed DateMay 21, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: shareholder-meeting, corporate-governance, filing

TL;DR

AC Immune SA is calling its shareholders to meetings on May 21, 2024.

AI Summary

AC Immune SA filed a Form 6-K on May 21, 2024, announcing an invitation to its Ordinary Shareholders' Meeting and its 2024 Annual General Meeting. The filing details the company's principal executive office located at EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland, and is signed by CEO Andrea Pfeifer and CFO Christopher Roberts.

Why It Matters

This filing provides shareholders with official notice and materials for upcoming important meetings where key company decisions and governance matters will be addressed.

Risk Assessment

Risk Level: low — This filing is a routine procedural document related to shareholder meetings and does not contain new financial or operational information that would typically impact risk.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

The purpose of this Form 6-K filing is to report an invitation to AC Immune SA's Ordinary Shareholders' Meeting and its 2024 Annual General Meeting.

Who signed this Form 6-K on behalf of AC Immune SA?

The Form 6-K was signed by Andrea Pfeifer, Chief Executive Officer, and Christopher Roberts, Chief Financial Officer.

Where is AC Immune SA's principal executive office located?

AC Immune SA's principal executive office is located at EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland.

What exhibits are included with this Form 6-K?

The exhibits included are Exhibit 99.1, an Invitation to the Ordinary Shareholders’ Meeting, and Exhibit 99.2, the 2024 Annual General Meeting materials.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

Filing Stats: 248 words · 1 min read · ~1 pages · Grade level 14.8 · Accepted 2024-05-21 08:00:53

Filing Documents

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 Commission File Number: 001-37891 AC IMMUNE SA (Exact name of registrant as specified in its charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AC IMMUNE SA By: /s/ Andrea Pfeifer Name: Andrea Pfeifer Title: Chief Executive Officer By: /s/ Christopher Roberts Name: Christopher Roberts Title: Chief Financial Officer Date: May 21, 2024 EXHIBIT INDEX Exhibit Number Description 99.1 * Invitation to the Ordinary Shareholders’ Meeting 99.2 * 2024 Annual General Meeting Proxy Card 99.3 Consolidated Financial Statements (IFRS) as at and for the years ended December 31, 2023, 2022 and 2021 (incorporated by reference to Item 18 of Part III of AC Immune’s Annual Report on Form 20-F for the fiscal year ended December 31, 2023 filed on March 14, 2024) 99.4 2023 Annual Report (incorporated by reference to Exhibit 99.2 to the AC Immune Report of Foreign Private Issuer on Form 6-K filed on March 14, 2024) * Filed herewith.

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing